[Immunosuppression in inflammatory bowel disease: When, how and how long?]

Area of Science:

• Gastroenterology and Immunology
• Pharmacology of IBD treatments

Context:

• Inflammatory bowel disease (IBD) management requires effective long-term strategies.
• Immunosuppressive therapies are central to achieving sustained remission in IBD patients.
• Specific patient profiles, including steroid-refractory disease, dependency, chronic activity, or frequent relapses, indicate the need for immunosuppression.

Purpose:

• To outline the role and available options for immunosuppressive treatment in IBD.
• To define patient eligibility criteria for immunosuppressive therapy.
• To highlight the importance of current guidelines in directing rational drug use.

Summary:

• Immunosuppressive agents are vital for treating inflammatory bowel disease (IBD) with the aim of achieving lasting remission.
• Treatment is indicated for patients with steroid-refractory disease, steroid dependency, chronic active disease, or frequent relapses.
• Available options include conventional immunosuppressives (azathioprine/6-mercaptopurine, methotrexate, cyclosporine A, tacrolimus) and anti-TNF antibodies (infliximab, adalimumab).
• Current guidelines provide a framework for the appropriate utilization of these immunosuppressive medications.

Impact:

• Facilitates evidence-based decision-making for clinicians managing IBD patients.
• Aims to optimize treatment outcomes and improve the quality of life for individuals with IBD.
• Supports the rational and effective use of immunosuppressive therapies in clinical practice.